商品介绍
Dapagliflozin (BMS-512148) is an orally-available C-aryl glucoside diphenylmethanol inhibitor of SGLT2 (IC50 1.1 nM) for the treatment of Type 1 and Type 2 diabetes. It is the first approved SGLT2 inhibitor (European Union as Forxiga) for the treatment of diabetes. Its excellent selectivity over SGLT1 (IC50 1390 nM) ensures that it does not interfere with intestinal glucose absorption. Dapagliflozin minimally inhibits glucose transporters GLUT1 and GLUT2 and modestly inhibits GLUT4. [1]Dapagliflozin removes excess glucose and its associated calories in urine, which in turn reduces blood sugar levels. Clinical studies have shown concurrent reductions in weight and blood pressure. [2] In combination with metformin, the weight loss was statistically significant, dose-dependent, and persisted for over two years. [3]
Technical information:
| Chemical Formula: | | C21H25ClO6 |
| CAS #: | | 461432-26-8 |
| Molecular Weight: | | 408.87 |
| Purity: | | >98% |
| Appearance: | | White |
| Chemical Name: | | (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol |
| Solubility: | | Up to 100 mM in DMSO |
| Synonyms: | | BMS-512148, BMS 512148, BMS512148, Dapagliflozin |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Shah et al., Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012, 32(1), 80-94. Pubmed ID:22392830 |
| 2. | AstraZeneca website: http://www.astrazeneca.com/Media/Press-releases/Article/20121114--forxiga-eu-approval-type-2-diabetes |
| 3. | Chao et al., Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evidence 2012, 7, 21-28. Pubmed ID:22701099 |
Other Information:
Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.
品牌介绍
Cellagen Technology 公司位于美国加州San Diego，该公司致力于干细胞相关产品的研发和生产。基于多年为世界*的生物公司提供OEM产品的经验，目前Cellagen Technology公司利用自身优势，拓展了原有产品线，推出了以StemRegenin 1（SR1）为代表的多种自有品牌产品。 NamePriceCat # （Powder）Cat # （10 mM in DMSO）Pathway/Target7,8-Dihydroxyflavone1173C7181-10N/ATrkBA7696622023C2769-10N/AAMPKA83-011513C2831-2C2831-2sTGF-β/ALK4,5,7Abiraterone1853C2247-2C2247-2sP450-CYP17BEZ235833C2392-2C2392-2sPI3K, mTORBIX-012941513C2491-5C2491-5sEpigenetics/G9a HMTCHIR990213553C2447-2C2447-2sGSK3β CP-6905501343C2716-2C2716-2sJAK1,2,3Cyclopamine2193C2925-2C2925-2sHedgehog/SmoDAPT1853C3178-5C3178-5sNotch/γ-secretaseForskolin1853C3677-10N/AAdenylate cyclaseFTY7201173C3897-5C3897-5sS1P receptorsGDC-09411513C4321-5C4321-5sPI3KHh-Ag1.53043C4412-2C4412-2sHedgehog/SmoINCB0184241853C4622-2C4622-2sJAK1/2IWP-31853BackorderBackorderWntKHS1011853C5471-5C5471-5sNeural differentiationLDE2252363C5332-2C5332-2sHedgehog/SmoLDN-1931893723C5361-2C5361-2sBMP/ALK2,3Leukadherin-1#VALUE!C5385-2C5385-2sCD11b, CD18LY2940022193C5929-5C5929-5sPI3KP7C32363C7723-10N/Aneurogenic, neuroprotectivePD03259013723C7303-2C7303-2sMEK1, MEK2PD03329912193C7306-2C7306-2sCdk4, Cdk6PS481343C7748-5C7748-5sPDK1Pyrintegrin3383C7974-1C7974-1sES cell survivalR4062193C7406-2C7406-2sSykR7883723C7788-5C7788-5sSykRapamycin2193C7272-5C7272-5smTORReversine1173C7383-2C7383-2sA3 Adenosine ReceptorRO49290972703C7649-2C7649-2sNotch/γ-secretaseSB4315421513C7243-5C7243-5sTGF-β/ALK4,5,7SF16703723C7316-2C7316-2spTENSitagliptin1513C7482-5C7482-5sDPP-4SRT17202363C7781-2C7781-2sSIRT1StemRegenin1 （SR1）3723C7710-1C7710-1sAryl hydrocarbon receptorSU54022703C7854-1C7854-1sFGFRThiazovivin3553C8442-1C8442-1sROCKUrsolic Acid1853C8776-10N/ASTAT3VX-6801173C8916-10N/AAurora kinaseWnt-C592703C7641-2C7641-2sWntXAV9392703C9289-2C9289-2sWntY-276321853C9127-2C9127-2sROCKhuman Activin A5423P4228-1031910 µg37383P4228-1002199100 µghuman BMP-4 3723P4267-1021910 µg25483P4267-1001499100 µghuman bFGF 3383P4234-5019950 µg23783P4234-5001399500 µgmouse LIF 3383P6543-1019910 µg23783P6543-1001399100 µghuman Wnt-3a 3723P4968-1021910 µg
